Navigation Links
"DES Daughters" Have High Risk Of Breast Cancer

"DES daughters", the girls born to mothers who took the anti-miscarriage drug diethylstilbestrol at the time of pregnancy have an increased risk of breast cancer//, according to a new study published in the August issue of the journal Cancer Epidemiology, Biomarkers & Prevention. Researchers found that DES daughters over age 40 had 1.9 times the risk of breast cancer than women who were not exposed to the drug.

They also found that the relative risk of developing the cancer was even greater in DES daughters over age 50, but say the number of older women in their study group is, as yet, too small for a firm statistical comparison.

"This is really unwelcome news because so many women worldwide were prenatally exposed to DES, and these women are just now approaching the age at which breast cancer becomes more common," said the study's lead author, Julie Palmer, Sc.D., professor of epidemiology at the Boston University School of Public Health.

She said an estimated one to two million women in the U.S. were exposed to DES, which was frequently prescribed to women from the 1940s through 1960s to prevent miscarriages.

The ongoing study suggests that DES-exposed women are developing the typical range of breast cancers after age 40 at a faster rate than non-exposed women of the same ages. The researchers also found that the highest relative risk of developing breast cancer was observed in study participants from the cohorts with the highest cumulative doses of DES exposure.

Because of the increased risk observed for DES daughters, the authors urge women who know they were exposed to DES to have regular screening mammograms, and to think twice about using supplemental female hormones.

"DES daughters often ask us about use of these hormones," Palmer said. "It might be wise for exposed women to avoid such supplements. Use of hormone supplements is, in itself, an independent breast cancer risk factor, and wo men may choose not to compound their already increased risk."

When DES, a synthetic estrogen, was developed in 1938, physicians believed that low levels of estrogen in pregnant women led to spontaneous abortions or premature deliveries. In 1953, a clinical trial indicated no benefit with regard to miscarriage prevention. However, use continued in the U.S. until 1971 when researchers determined that DES greatly increased the risk of developing rare cancers of the vagina and cervix in DES daughters; the federal Food and Drug Administration subsequently banned use of the drug in pregnant women.

Later research demonstrated that DES increased the risk of breast cancer development in the mothers who used it.

To see if DES daughters and sons were also at greater risk of cancer or other serious illnesses, in 1992 the National Cancer Institute (NCI) funded a long-term study that assembled all known "cohorts," or groups of DES daughters that were already being studied (some since the 1970s), as well as a collection of unexposed women. This particular analysis included 4,817 exposed and 2,073 unexposed daughters, and, to date, 102 cases of invasive breast cancer have occurred in the combined group.

Factoring out other breast cancer risk variables such as the age when these women first gave birth, or their number of children, did not change DES daughters' relative risk of developing breast cancer, Palmer said. She adds that the breast cancer cases "tracked the normal range" of breast cancer subtypes, so are expected to be neither more nor less lethal than is commonly seen.

Only a few deaths have occurred in the combined group due to breast cancer, so survival statistics are not yet available, she said.

Scientifically, the study may be the first to provide direct evidence that prenatal exposure to excess estrogen may be a risk factor for development of breast cancer, Palmer said. "That theory has been around , but it has been difficult to study. The DES tragedy offers us a direct way to test the hypothesis," she said.

Although researchers do not know how DES may increase breast cancer risk, Palmer said some scientists believe the excess estrogen increases the number of breast tissue stem cells available at birth − cells which could malignantly transform into cancer.

If true that excess estrogen in utero impacts breast cancer risk later in life, "there is a concern that other environmental factors that increases fetal exposure to estrogenic compounds may do the same thing," Palmer said. "This study suggests that such environmental exposures may deserve more serious consideration."

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
Source: Eurekalert
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The American ... for the scientific development, healthcare training and clinical application of medical infrared imaging, ... AAT Member Certification Qualification Courses for Technicians, respectively. , For the first time ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture ... choosing the right method is paramount to success. Selecting an inappropriate measurement method ... where multiple persons use the same equipment. Rare or expensive substances are wasted ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Old School Labs™, ... added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team of brand ... a bodybuilder in 2012 and in less than a year was able to turn ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... SAN DIEGO , Jan. 20, 2017 ResMed (NYSE: ... and 3B Medical ( Winter Haven, Florida ) today ... between the parties. BMC and 3B will be permitted to sell ... ResMed will make a one-time settlement payment to 3B to close ... The settlement did not include an admission of liability or wrongdoing ...
(Date:1/21/2017)... Jan. 20, 2017  Faruqi & Faruqi, LLP, a leading ... or the "Company") (NASDAQ: KMPH ) of the ... certain officers and directors and underwriters of the Company,s April ... role of lead plaintiff. The lawsuit has been ... for Johnson County on behalf of ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: